Literature DB >> 18077614

Performance characteristics of microparticle enzyme and chemiluminescence immunoassays for measurement of anti-HBc immunoglobulin M in sera of patients with HBeAg-negative chronic hepatitis B virus infection.

Emilia Hadziyannis1, Emanuel Manesis, Dimitrios Vassilopoulos, Anastasia Georgiou, Athanasios Archimandritis.   

Abstract

The IMx, AxSym, and Architect immunoglobulin M anti-HBc assay systems for detecting hepatitis B virus e antigen-negative chronic hepatitis B virus infection were compared. Despite good intra- and interassay coefficients of variation, significantly different values and low correlation (overestimation by AxSym and underestimation by Architect) were observed. Association and cutoff values for distinguishing patients with viral replication should be established for all methods.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18077614      PMCID： PMC2238054          DOI： 10.1128/CVI.00414-07

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN： 1556-679X


  24 in total

1.  Detection of IgM to hepatitis B core antigen in a reductant containing, chemiluminescence assay.

Authors:  Y Cheng; N Dubovoy; M E Hayes-Rogers; J Stewart; D Shah
Journal:  J Immunol Methods       Date:  1999-11-19       Impact factor: 2.303

2.  Semiquantitative assessment of IgM antibody to hepatitis B core antigen and prediction of the severity of chronic hepatitis B.

Authors:  G Colloredo; G Bellati; A Sonzogni; C Zavaglia; O Fracassetti; G Leandro; R Ghislandi; E Minola; G Ideo
Journal:  J Viral Hepat       Date:  1999-11       Impact factor: 3.728

3.  Are alanine aminotransferase, hepatitis B virus DNA or IgM antibody to hepatitis B core antigen serum levels predictors of histological grading in chronic hepatitis B?

Authors:  C Zavaglia; L Mondazzi; G Maggi; G Iamoni; F Gelosa; G Bellati; G Colloredo; R Bottelli; G Ideo
Journal:  Liver       Date:  1997-04

4.  Quantitative analysis of IgM anti-HBc in chronic hepatitis B patients using a new "gray-zone" for the evaluation of "borderline" values.

Authors:  G Colloredo; G Bellati; G Leandro; P Colombatto; A Rho; F Bissoli; M R Brunetto; G Angeli; G Ideo; F Bonino
Journal:  J Hepatol       Date:  1996-11       Impact factor: 25.083

5.  Poor response to 18-month lamivudine monotherapy in chronic hepatitis B patients with IgM anti-HBc and acute exacerbation.

Authors:  J-J Chen; C-Y Lin; M-J Sheu; H-T Kuo; C-S Sun; L-Y Tang; S-L Wang; S-L Tsai
Journal:  Aliment Pharmacol Ther       Date:  2006-01-01       Impact factor: 8.171

6.  Quantitative analysis of HBsAg, IgM anti-HBc and anti-HBc avidity in acute and chronic hepatitis B.

Authors:  Anna Rodella; Claudio Galli; Luigina Terlenghi; Francesca Perandin; Carlo Bonfanti; Nino Manca
Journal:  J Clin Virol       Date:  2006-08-08       Impact factor: 3.168

Review 7.  Diagnosis and management of pre-core mutant chronic hepatitis B.

Authors:  G V Papatheodoridis; S J Hadziyannis
Journal:  J Viral Hepat       Date:  2001-09       Impact factor: 3.728

8.  Evaluation of two chemiluminescent immunoassays of ADVIA Centaur for hepatitis B serology markers.

Authors:  Dan Chen; Lawrence Kaplan; Qiang Liu
Journal:  Clin Chim Acta       Date:  2005-05       Impact factor: 3.786

9.  Virological profiles in hepatitis B virus inactive carriers: monthly evaluation in 1-year follow-up study.

Authors:  Irene Cacciola; Giovanna Spatari; Teresa Pollicino; Lucy Costantino; Giovanni Zimbaro; Santa Brancatelli; Concettina Fenga; Gaia Caccamo; Giovanni Squadrito; Giovanni Raimondo
Journal:  Liver Int       Date:  2005-06       Impact factor: 5.828

Review 10.  Treatment of chronic anti-HBe-positive hepatitis B with interferon-alpha.

Authors:  M R Brunetto; F Oliveri; P Colombatto; M Capalbo; C Barbera; F Bonino
Journal:  J Hepatol       Date:  1995       Impact factor: 25.083
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.